FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
Jiang M, Wu C, Zhang L, Sun C, Wang H, Xu Y, Sun H, Zhu J, Zhao W, Fang Q, Yu J, Chen P, Wu S, Zheng Z, He Y, Zhou C.
Jiang M, et al. Among authors: zhou c.
J Immunother Cancer. 2021 May;9(5):e002339. doi: 10.1136/jitc-2021-002339.
J Immunother Cancer. 2021.
PMID: 34006632
Free PMC article.